In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified ...

Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market businesses, announced today its ...

Compass Diversified (NYSE: CODI) announced it will release its financial results for the fourth quarter and full year ending December 31, 2024, on February 27, 2025, after market close. A conference ...

Compass has resolved the significant issues with its financial filings, known as material weaknesses, meeting a self-imposed deadline. The disclosure generally refers to a systemic problem at a ...

MSCI Inc. (NYSE: MSCI) is enhancing its index calculation capabilities in alternative and multi-asset classes, including commodities and cryptocurrencies, through the acquisition of index services ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Compass Minerals (NYSE: CMP), a leading global provider of essential minerals, today announced the appointment of Jeffrey Cathey as the company’s new chief ...

Compass, Inc., d/b/a Compass International Holdings ("Compass" or "the Company"), (NYSE: COMP) a global real estate services company with a presence in every major U.S. city and approximately 120 ...

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe ...